Upstream Bio's Verekitug Hits Phase 2 Goals in Severe Asthma Trial
Event summary
- Verekitug reduced annualized asthma exacerbation rate (AAER) by 56% (100 mg q12w) and 39% (400 mg q24w) vs. placebo in Phase 2 VALIANT trial.
- Lung function (FEV1) improved by 122 mL (100 mg q12w) and 139 mL (400 mg q24w) at week 60.
- Over 90% of eligible patients rolled over to the Phase 2 VALOUR long-term extension study.
- Upstream Bio plans to advance verekitug into Phase 3 trials for severe asthma and CRSwNP following regulatory discussions.
The big picture
Upstream Bio's positive Phase 2 results for verekitug position the company to challenge existing biologics in the severe asthma market. The drug's differentiated dosing profile and robust efficacy data could make it a strong contender, provided regulatory hurdles are cleared. The company's focus on multiple inflammatory diseases, including CRSwNP and COPD, suggests a broader strategic play in respiratory disorders.
What we're watching
- Regulatory Pathway
- Whether Upstream Bio can secure regulatory approval for verekitug based on current Phase 2 data.
- Competitive Positioning
- How verekitug's less frequent dosing compares to existing biologics in the severe asthma market.
- Clinical Development
- The pace at which Upstream Bio advances verekitug into Phase 3 trials for severe asthma and CRSwNP.
Related topics